Agendia NV (Agendia) is a molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. The company discovers, develops and commercializes products for the treatment of cancer. Its products comprise mammaprint, blueprint, targetprint, coloprint, theraprint for breast cancer, theraprint for colon cancer, and symphony, and among others. Agendia product MammaPrint provides individualized metastasis risk assessment of breast cancer patients. The company collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. It also has presence in the US, Canada, Spain, Japan, Germany, Mexico, Korea and others. Agendia is headquartered in Amsterdam, the Netherlands.
Agendia NV - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025). Certain factors that are driving the market growth include increased awareness about the potential benefits of targeted alpha therapy and the growing number of patients with cardiac and cancer ailments. Targeted anticancer...
INTRODUCTION The introduction of personalized medicine has brought about a paradigm shift within the healthcare sector. Over the years, many cases have been identified where conventional treatment options have failed to demonstrate any therapeutic benefit. It is estimated that nearly 50% of prescribed drugs / therapies...
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Congenital Adrenal Hyperplasia in 31 Major Markets Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Multiple Myeloma in 18 Major Markets
Multiple Myeloma is a cancer of plasma cells and is characterized by the production of abnormal immunoglobulins (Ig) or antibodies, as well as an accumulation of malignant plasma cells in the bone marrow. In some cases it...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Brain & CNS Cancer in 19 Major Markets
Primary brain and central nervous system (CNS) tumours (ICD-10 codes C70-C72) are a group of primary tumours arising in the brain, meninges or central nervous system. As such, this is a cluster of conditions rather than...
Summary Immutep SA (Immutep) a subsidiary of Institut Gustave Roussy is a biopharmaceutical company that develops immunotherapeutics in oncology. The company offers products such as human protein immunostimulatory factors for the treatment of cancer and therapeutic antibodies for the modulation of immune system in cancer, autoimmune...
Summary Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company, which develops and commercializes innovative medicines that target the molecular mechanisms causing cancer. It has two oncology franchises one in kinase inhibition and other in proteasome inhibition. The company marketed product portfolio includes Nexavar...
DFine Inc (DFine) is a medical device company that develops therapeutic devices for treatment of pathologies of vertebrae. The company offers products such as tumor ablation system, vertebral augmentation system, MX and VP vertebroplasty system, and multiplex controller. It also provides delivery cannula, midline and...
Summary NovioGendix Holding BV (NovioGendix), a subsidiary of MDxHealth SA is a biotechnology company that offers molecular diagnostic research and service. The company develops clinically useful molecular diagnostic assays for the uro-oncological diseases. Its projects under clinical trial development include prostate cancer, bladder...
RedHill Biopharma Ltd (RedHill) is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases and cancer. The company’s pipeline products include oral combination therapy candidates for the treatment of helicobacter...
Digestive System Disorder
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.